1. Home
  2. CELC vs LAZ Comparison

CELC vs LAZ Comparison

Compare CELC & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celcuity Inc.

CELC

Celcuity Inc.

N/A

Current Price

$53.29

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Logo Lazard Inc.

LAZ

Lazard Inc.

N/A

Current Price

$35.59

Market Cap

3.4B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CELC
LAZ
Founded
2011
1848
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
3.4B
IPO Year
2017
2004

Fundamental Metrics

Financial Performance
Metric
CELC
LAZ
Price
$53.29
$35.59
Analyst Decision
Strong Buy
Hold
Analyst Count
13
10
Target Price
★ $150.85
$43.38
AVG Volume (30 Days)
920.9K
★ 1.4M
Earning Date
11-05-2026
10-22-2026
Dividend Yield
N/A
★ 5.32%
EPS Growth
N/A
★ N/A
EPS
N/A
★ 1.20
Revenue
N/A
★ $3,186,466,000.00
Revenue This Year
N/A
$5.98
Revenue Next Year
$1,921.71
$19.40
P/E Ratio
★ N/A
$31.33
Revenue Growth
N/A
★ 1.48
52 Week Low
$53.54
$34.13
52 Week High
$151.02
$58.75

Technical Indicators

Market Signals
Indicator
CELC
LAZ
Relative Strength Index (RSI) 30.06 38.25
Support Level N/A $34.65
Resistance Level $72.76 $37.58
Average True Range (ATR) 4.24 1.68
MACD -1.03 -0.39
Stochastic Oscillator 0.16 0.14

Price Performance

Historical Comparison
CELC
LAZ

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

About LAZ Lazard Inc.

Lazard Inc is a financial advisory and asset management firm with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Geographically, the company earns key revenue in the Americas, EMEA then Asia-Pacific.

Share on Social Networks: